As part of a wider conversation about global life sciences talent, recruiter Michael Woodhead and commercial strategy specialist Kaiser Karamdad turned their attention to a question that carries real implications for US life sciences leaders and professionals: why does the US, with a smaller share of STEM graduates than the UK, consistently build a deeper and more commercially mature life sciences workforce?
I think it is fair to say that the United Kingdom punches well above its weight in life sciences. It has world-class academic institutions, a strong track record in early-stage company formation, and a culture that produces genuinely exceptional science. And yet, when it comes to scaling that science into sustainable commercial businesses, the UK consistently falls short.
It is easy to take for granted just how mature the American life sciences talent ecosystem has become. The US has world-class academic institutions of its own, but what sets it apart is not the science. It is the infrastructure that turns early science into scaled, commercially successful companies, and the career pathways that keep experienced talent moving through that system.
That distinction matters for anyone hiring in US life sciences, or building a career within it. Understanding why the American model works, particularly in contrast to markets like the UK, helps explain where the real opportunities and talent gaps sit right now.
A striking contrast in numbers of early interest from graduates
Consider this: roughly 19% of US graduates hold STEM degrees, compared to approximately 42% in the UK. And yet around 1.4% of the US workforce is employed in life sciences, versus just 0.8% in the UK. The UK has more than double the proportion of STEM graduates, but the US still ends up with nearly twice the share of its workforce actually working in life sciences.
That gap is not about talent supply. It is about how effectively a market converts scientific graduates into sustainable, scaled commercial careers. On that measure, the US model is doing something right that other markets, including the UK, have not yet replicated.
A career and established pathway that already works
One area where the American system is well ahead is the movement of physicians into industry. In the US, it is common and culturally accepted for clinicians to move sponsor-side, into roles such as medical directors, chief medical officers, or clinical development leads. The pathway is established, well understood, and actively pursued.
That is not the case everywhere. In the UK, for example, that crossover happens far less often, largely because clinicians simply are not exposed to the idea that the path exists. The practical effect is that UK companies often struggle to fill senior medical and clinical development roles, while US companies benefit from a much deeper, more visible bench of physician talent willing to make that move.
For US professionals, this is worth recognizing as a genuine competitive advantage, and one that continues to create strong demand for experienced clinical and medical leadership talent.
Why global science keeps ending up under US ownership
The talent pipeline is only part of the story. The deeper structural advantage sits in capital. As Kaiser puts it directly:
“The UK excels at creating companies and world-class science early-stage but lacks the infrastructure for scaling compared to the US.”
Markets like the UK are genuinely good at starting companies and producing early-stage science. What they consistently lack, relative to the US, is the scale-up capital: large venture funds, deep growth equity, and institutional investors with the risk appetite for long development timelines. The US has that infrastructure in abundance, and the consequence, as Kaiser notes, is significant:
“UK biotechs often bring in US investors or VCs, resulting in US ownership of UK science, which represents a loss of UK science and offshoring of intellectual property.”
For the US life sciences sector, this pattern is a genuine strength. American capital depth is a major reason so much promising international science, not just from the UK but from other markets with strong early-stage ecosystems and thinner scale-up infrastructure, ends up being commercialized on US soil, under US ownership, and staffed by US teams.
What this means for US Life Science professionals
This dynamic is not just an academic point about capital markets. It has direct implications for hiring and careers in the US:
- Demand for talent who can integrate acquired international assets, including scientific, regulatory, and operational expertise, continues to grow as US companies bring in overseas science.
- Business development and licensing professionals who understand how to evaluate and structure cross-border deals are increasingly valuable.
- Clinical development and medical affairs leaders with international experience are well positioned, given how much of the underlying science now originates outside the US.
- The established clinician-to-industry pathway in the US remains a significant advantage for building senior medical and scientific leadership benches, and one worth continuing to invest in.
The US has built an ecosystem that most other markets, including the UK, are still trying to replicate: capital deep enough to scale ambitious science, and career pathways mature enough to keep experienced talent flowing into industry. That combination is precisely why the US continues to be a magnet for international science and the talent needed to commercialize it.
Building or scaling a life sciences team in the US comes with its own challenges, particularly around finding leaders who can manage increasingly global science and deal flow. The right recruitment partner can make a meaningful difference. Whether you are building a function from scratch or strengthening an existing team, get in touch to find out more about how we can support you.
Scaling a life sciences team comes with unique challenges, but the right recruitment partner can make a significant difference. Whether you're building from scratch or strengthening an existing function, I have the network and sector knowledge to support you. Get in touch with me to find out more about how I can support.
____________________________________________________________________________________________________________________
Michael Woodhead Associate Director, Consult Search
Michael has been recruiting in the life sciences sector for seven years, specializing in building teams across biometrics, clinical development, research, and medical affairs. His focus spans senior individual contributors through to leadership level, with particular depth in biostatistics, statistical programming, and data management. Prior to life sciences, Michael spent five years recruiting across technical industries. He works with biotech, biopharma, and CRO clients across the United States and Europe.
Kaiser Karamdad Life Sciences Commercial Strategy Specialist
Kaiser holds a PhD from Imperial College London in synthetic biology and chemical biology, and has spent his career at the intersection of science and commercial strategy. He began at Cambridge Healthcare Research, supporting pharma and biotech clients on commercial planning and business development, before moving into industry as Chief of Staff to the CEO at Achilles Therapeutics, a cell therapy company that IPO'd on NASDAQ in 2021. Most recently, Kaiser served as BD Director at Quell Therapeutics, a CAR-Treg focused cell therapy company, where he led partnering strategy and commercial value proposition. He is currently exploring his next opportunity in business development and commercial leadership within the life sciences sector.